Moderna and Pfizer-BioNTech vaccines prime T cells to fight SARS-CoV-2 variants
LJI researchers highlight the importance of T cell cross reactivity in stopping severe COVID-19 cases
In-Depth: La Jolla Institute takes comprehensive look at COVID-19 immunity
Study compares four vaccines and natural immunity
LJI and Synbal, Inc. partner to develop better COVID-19 models
New mouse models may shed light on the puzzling aspects of SARS-CoV-2 infection
A COVID-fighter’s guide to T cells
New LJI review shows how T cells target more than 1,400 sites on SARS-CoV-2
The new CEO of the La Jolla Institute for Immunology ascended by lifting others
Erica Ollman Saphire brings together scientific competitors to find new antibody therapeutics for COVID-19.
Learning from men. Learning from women.
Men and women have different immune systems. With a better understanding of sex-specific immune differences, scientists can more effectively fight infections, cancers, heart disease, and even pregnancy complications.
Tempus dare: A time to give
San Diego biotech entrepreneurs François Ferré, Ph.D., and Magda Marquet, Ph.D., knew supporting LJI would be critical for advancing our understanding of COVID-19.
Q&A with Bjoern Peters, Ph.D.
The bioinformatics tools Dr. Peters has developed are invaluable for immunologists worldwide.
If You Don’t Have COVID Vaccine Side Effects, Are You Still Protected?
Reactions reflect unique features of an individual’s immune system, not the strength of a response
Your Immune System Evolves to Fight Coronavirus Variants
Antibodies can change to counter new forms of the shape-shifting virus, research hints